Find information on thousands of medical conditions and prescription drugs.

CREST syndrome

Scleroderma is a rare, chronic disease characterized by excessive deposits of collagen. Progressive systemic scleroderma or systemic sclerosis, the generalised type of the disease, can be fatal. The localised type of the disease tends not to be fatal. The term 'localised, generalised sclerderma' can be used to describe cases where the disease covers a large area of the body - typically more than 40%. more...

Home
Diseases
A
B
C
Angioedema
C syndrome
Cacophobia
Café au lait spot
Calcinosis cutis
Calculi
Campylobacter
Canavan leukodystrophy
Cancer
Candidiasis
Canga's bead symptom
Canine distemper
Carcinoid syndrome
Carcinoma, squamous cell
Carcinophobia
Cardiac arrest
Cardiofaciocutaneous...
Cardiomyopathy
Cardiophobia
Cardiospasm
Carnitine transporter...
Carnitine-acylcarnitine...
Caroli disease
Carotenemia
Carpal tunnel syndrome
Carpenter syndrome
Cartilage-hair hypoplasia
Castleman's disease
Cat-scratch disease
CATCH 22 syndrome
Causalgia
Cayler syndrome
CCHS
CDG syndrome
CDG syndrome type 1A
Celiac sprue
Cenani Lenz syndactylism
Ceramidase deficiency
Cerebellar ataxia
Cerebellar hypoplasia
Cerebral amyloid angiopathy
Cerebral aneurysm
Cerebral cavernous...
Cerebral gigantism
Cerebral palsy
Cerebral thrombosis
Ceroid lipofuscinois,...
Cervical cancer
Chagas disease
Chalazion
Chancroid
Charcot disease
Charcot-Marie-Tooth disease
CHARGE Association
Chediak-Higashi syndrome
Chemodectoma
Cherubism
Chickenpox
Chikungunya
Childhood disintegrative...
Chionophobia
Chlamydia
Chlamydia trachomatis
Cholangiocarcinoma
Cholecystitis
Cholelithiasis
Cholera
Cholestasis
Cholesterol pneumonia
Chondrocalcinosis
Chondrodystrophy
Chondromalacia
Chondrosarcoma
Chorea (disease)
Chorea acanthocytosis
Choriocarcinoma
Chorioretinitis
Choroid plexus cyst
Christmas disease
Chromhidrosis
Chromophobia
Chromosome 15q, partial...
Chromosome 15q, trisomy
Chromosome 22,...
Chronic fatigue immune...
Chronic fatigue syndrome
Chronic granulomatous...
Chronic lymphocytic leukemia
Chronic myelogenous leukemia
Chronic obstructive...
Chronic renal failure
Churg-Strauss syndrome
Ciguatera fish poisoning
Cinchonism
Citrullinemia
Cleft lip
Cleft palate
Climacophobia
Clinophobia
Cloacal exstrophy
Clubfoot
Cluster headache
Coccidioidomycosis
Cockayne's syndrome
Coffin-Lowry syndrome
Colitis
Color blindness
Colorado tick fever
Combined hyperlipidemia,...
Common cold
Common variable...
Compartment syndrome
Conductive hearing loss
Condyloma
Condyloma acuminatum
Cone dystrophy
Congenital adrenal...
Congenital afibrinogenemia
Congenital diaphragmatic...
Congenital erythropoietic...
Congenital facial diplegia
Congenital hypothyroidism
Congenital ichthyosis
Congenital syphilis
Congenital toxoplasmosis
Congestive heart disease
Conjunctivitis
Conn's syndrome
Constitutional growth delay
Conversion disorder
Coprophobia
Coproporhyria
Cor pulmonale
Cor triatriatum
Cornelia de Lange syndrome
Coronary heart disease
Cortical dysplasia
Corticobasal degeneration
Costello syndrome
Costochondritis
Cowpox
Craniodiaphyseal dysplasia
Craniofacial dysostosis
Craniostenosis
Craniosynostosis
CREST syndrome
Cretinism
Creutzfeldt-Jakob disease
Cri du chat
Cri du chat
Crohn's disease
Croup
Crouzon syndrome
Crouzonodermoskeletal...
Crow-Fukase syndrome
Cryoglobulinemia
Cryophobia
Cryptococcosis
Crystallophobia
Cushing's syndrome
Cutaneous larva migrans
Cutis verticis gyrata
Cyclic neutropenia
Cyclic vomiting syndrome
Cystic fibrosis
Cystinosis
Cystinuria
Cytomegalovirus
Dilated cardiomyopathy
Hypertrophic cardiomyopathy
Restrictive cardiomyopathy
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Medicines

Signs and symptoms

Scleroderma affects the skin, and in more serious cases, it can affect the blood vessels and internal organs. The most evident symptom is the hardening of the skin and associated scarring. Typically the skin appears reddish or scaly in appearance. Blood vessels may also be more visible. Where large areas are affected, fat and muscle wastage will weaken limbs and affect appearance.

The seriousness of the disease varies hugely between cases. The two most important factors to consider are, the level of internal involvement (beneath the skin), and the total area covered by the disease. For example there are cases where the patient has no more than one or two lesions (affected areas), perhaps covering a few inches. These are less serious cases and tend not to involve the internal bodily functions.

Cases with larger coverage are far more likely to affect the internal tissues and organs. Where an entire limb is affected, symptoms will almost certainly have serious consequences on the use of that limb. The heart and lungs will be affected when the disease covers this area of the torso. Some patients also experience gastrointestinal problems, including heartburn and acid reflux. Internal scarring may sometimes spread beyond what can be seen by the naked eye.

There is discoloration of the hands and feet in response to cold. Most patients (>80%) have Raynaud's phenomenon, a vascular symptom that can affect the fingers, and toes.

Systemic scleroderma and Raynaud's can cause painful ulcers on the fingers or toes, which are known as digital ulcers.

Types

There are three major forms of scleroderma: diffuse, limited (CREST syndrome) and morphea/linear. Diffuse and limited scleroderma are both a systemic disease, whereas the linear/morphea form is localized to the skin. (Some physicians consider CREST and limited scleroderma one and the same, others treat them as two separate forms of scleroderma.)

Diffuse scleroderma

Diffuse scleroderma is the most severe form - it has a rapid onset, involves more widespread skin hardening, will generally cause much internal organ damage (specifically the lungs and gastrointestinal tract), and is generally more life threatening.

Limited scleroderma/CREST syndrome

The limited form is much milder: it has a slow onset and progression, skin hardening is usually confined to the hands and face, internal organ involvement is less severe, and a much better prognosis is expected.

The limited form is often referred to as "CREST" syndrome. CREST is an acronym for:

  • Calcinosis
  • Raynaud's syndrome
  • Esophageal dysmotility
  • Sclerodactyly
  • Telangiectasia

These five are the major symptoms of the CREST syndrome.

Read more at Wikipedia.org


[List your site here Free!]


Pulmonary veno-occlusive disease in association with crest syndrome : clinical, radiologic, hemodynamic and pathologic characterization
From CHEST, 10/1/05 by William T. Mansfield

PURPOSE: Pulmonary Arterial Hypertension (PAH) is a rare disease sometimes associated with collagen vascular diseases, usually Limited Scleroderma (CREST Syndrome). Pulmonary Veno-occlusive Disease (PVOD) is an uncommon subtype of PAH with a particularly poor prognosis. PVOD is usually idiopathic, however it has also been associated with chemotherapy exposure and rheumatic diseases. PVOD has rarely been associated with CREST Syndrome, however few clinical data exist concerning this connection. We present clinical, radiographic, hemodynamic and pathologic data on two patients with PVOD and associated CREST Syndrome.

METHODS: Two patients managed at our institution for PVOD with concomitant CREST Syndrome were studied via retrospective chart analysis. All available clinical, radiographic, hemodynamic, and pathologic data were reviewed.

RESULTS: Two female patients (aged 63 and 71 years) were diagnosed with CREST Syndrome (8 and 20 years) prior to onset of pulmonary hypertension symptoms or diagnosis. Both were treated with nifedipine, prednisone, and cyclophosphamide for scleroderma, and warfarin, oxygen and epoprostenol for PAH. One received sitaxsentan prior to epoprostenol initiation. Both presented with dyspnea, (WHO Class III), accentuated P2 heart sound, RV heave, and II/VI tricuspid regurgitation murmurs. Both were seropositive for anticentromere antinuclear antibodies (titres: 1:1280 and 1:2048). Thoracic CTs demonstrated very mild interstitial Lung Disease (ILD). PFTs showed mild reductions in TLC with marked reductions in DLCO. Right heart catheterization showed: mean PAP 53 and 63 mmHg, PCWP 14 and 7 mmHg, CO 3.1 and 2.2 L/min, MVO2 44 and 37%, RAP 14 and 9 mmHg, respectively. Clinical courses were notable for rapid clinical deterioration (death within several weeks) characterized by progressive right heart failure, pleural effusions and pulmonary edema when given epoprostenol. Autopsies demonstrated PVOD without significant ILD in both cases.

CONCLUSION: PVOD and CREST Syndrome are two relatively rare conditions which may co-exist. The association carries a particularly poor prognosis in these cases, marked by clinical deterioration upon initiation of epoprostenol.

CLINICAL IMPLICATIONS: Clincians should consider PVOD in patients with scleroderma and pulmonary hypertension, particularly if thoracic CT scanning suggests ILD.

DISCLOSURE: William Mansfield, Grant monies (from industry related sources) Encysive, LP Myogen Biopharmaceutical; Product/procedure/technique that is considered research and is NOT yet approved for any purpose, sitaxsentan.

William T. Mansfield MD * Linda Allred RN Thomas E. Van der Kloot MD Joel A. Wirth MD Maine Medical Center, Portland, ME

COPYRIGHT 2005 American College of Chest Physicians
COPYRIGHT 2005 Gale Group

Return to CREST syndrome
Home Contact Resources Exchange Links ebay